Recent progress in our understanding of breast cancer biology resulting from studies using different molecular profiling techniques has yielded a complex picture of the mechanisms driving tumour progression. At the same time, a variety of different molecular-targeting agents have been developed for the treatment of patients with breast cancer. It has gradually become difficult for many of us to understand which pathways are inhibited by which targeted drugs. This progress was discussed in a recent article by Rimawi and Osborne (Breast cancer: Blocking both driver and escape pathways improves outcomes. Nat. Rev. Clin. Oncol. 9, 133–134).1
We propose here that the complex breast cancer model can be understood by comparing it to a hybrid vehicle with two power sources, such as the Toyota Prius. The Prius uses an electric motor and a gasoline-powered engine simultaneously or independently, and each power source affects the other. Also, the car has a monitor showing which power source is currently active and how the two power sources work together when the car is running. According to our current knowledge about breast cancer biology, the two main power sources in breast cancer are the oestrogen receptor (ER) and HER2. Figure 1 shows how these two 'power sources' act in concert with one other to promote breast cancer tumorigenesis. In the absence of oestradiol (petrol in our analogy), the membrane receptor-activated PI3K pathway and the MAPK pathway (motor and transmission) cause phosphorylation of ER (engine) and activate ER downstream genes (transmission).2,3 The impact on breast cancer of endocrine therapy, cytotoxic therapies, and targeted therapies, including antiangiogenesis agents, are illustrated in Figure 1b. This hybrid car analogy can also be used to illustrate the basic mechanisms of action in the recently reported BOLERO-2 trial,4 in which patients with ER-positive breast cancer were treated with a combination of the mTOR inhibitor everolimus and the aromatase inhibitor exemestane (Figure 1c). Of course, if we had a monitor analogous to the Prius's monitor indicating the power sources active in each patient's breast tumour, treatment choice would become dramatically easier.
Our simple hybrid car model could be a useful educational model for clinical oncologists who need to understand breast cancer biology and how best to employ the newly developed targeted therapies.
Rimawi, M. F. & Osborne, C. K. Breast cancer: Blocking both driver and escape pathways improves outcomes. Nat. Rev. Clin. Oncol. 9, 133–134 (2012).
Miller, T. W., Balko, J. M. & Arteaga, C. L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J. Clin. Oncol. 29, 4452–4461 (2011).
Osborne, C. K. & Schiff, R. Mechanisms of endocrine resistance in breast cancer. Ann. Rev. Med. 62, 233–247 (2011).
Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2011).
S. Saji receives research support from Chugai/Roche and Novartis. F. Sato receives research support from AstraZeneca and Chugai/Roche. N. T. Ueno receives research support from Kyowa Hakko Kirin.
About this article
Breast Cancer (2018)
International Journal of Clinical Oncology (2015)
Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells
FEBS Letters (2013)